MedTrace Logo

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

NCT03661723 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma.

The drugs involved in this study are:

* Pembrolizumab
* Radiation
* Bevacizumab, an FDA-approved drug for treating recurrent glioblastoma multiforme (GBM)

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system

DRUG

Bevacizumab

Bevacizumab (also known as "Avastin") is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.

RADIATION

Re-irradiation

Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine

Sponsors & Collaborators

Principal Investigators

  • David A Reardon, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2021-12-09
Completion
2024-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03661723 on ClinicalTrials.gov